Phase I/II Trial of the Combination of 177 Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN).

MLA

Crumbaker, Megan, et al. “Phase I/II Trial of the Combination of 177 Lutetium Prostate Specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN).” European Urology Oncology, vol. 4, no. 6, Dec. 2021, pp. 963–70. EBSCOhost, https://doi.org/10.1016/j.euo.2020.07.002.

APA

Crumbaker, M., Pathmanandavel, S., Yam, A. O., Nguyen, A., Ho, B., Chan, L., Ende, J. A., Rofe, C., Kongrak, K., Kwan, E. M., Azad, A. A., Sharma, S., Pugh, T. J., Danesh, A., Keane, J., Eu, P., Joshua, A. M., & Emmett, L. (2021). Phase I/II Trial of the Combination of 177 Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN). European Urology Oncology, 4(6), 963–970. https://doi.org/10.1016/j.euo.2020.07.002

Chicago

Crumbaker, Megan, Sarennya Pathmanandavel, Andrew O Yam, Andrew Nguyen, Bao Ho, Lyn Chan, Jesse A Ende, et al. 2021. “Phase I/II Trial of the Combination of 177 Lutetium Prostate Specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN).” European Urology Oncology 4 (6): 963–70. doi:10.1016/j.euo.2020.07.002.